- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03734029
Трастузумаб Дерукстекан (DS-8201a) по сравнению с выбором исследователя для лечения HER2-низкого рака молочной железы, который распространился или не может быть удален хирургическим путем [DESTINY-Breast04]
Фаза 3, многоцентровое, рандомизированное, открытое, активное контролируемое исследование DS-8201a, лекарственного конъюгата анти-HER2-антитело (ADC), по сравнению с лечением по выбору врача для пациентов с низким уровнем HER2, нерезектабельным и/или метастатическим раком молочной железы
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.
Participants' cancer:
- Cannot be removed by an operation
- Has spread to other parts of the body
Обзор исследования
Статус
Условия
Подробное описание
This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.
The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Innsbruck, Австрия, 6020
- Medizinische Universität Innsbruck
-
Linz, Австрия, 4020
- Kepler Universitätsklinikum
-
Salzburg, Австрия, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Австрия, 1090
- AKH - Medizinische Universität Wien (4305)
-
Wels, Австрия, 4600
- Klinikum Wels-Grieskirchen GmbH
-
-
-
-
-
Brussels, Бельгия, 1000
- Institut Jules Bordet
-
Brussels, Бельгия, 1090
- Universitair Ziekenhuis Brussel
-
Brussels, Бельгия, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, Бельгия, 3000
- UZ Leuven
-
Loverval, Бельгия, 6280
- Grand Hôpital de Charleroi
-
Namur, Бельгия, 5000
- CHU UCL Namur
-
Tournai, Бельгия, 7500
- Centre Hospitalier Wallonie picarde - Site IMC
-
-
-
-
-
Budapest, Венгрия, 1097
- Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
-
Budapest, Венгрия, 1122
- Orszagos Onkologiai Intezet
-
Debrecen, Венгрия, 4032
- Debreceni Egyetem
-
Gyula, Венгрия, 5700
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
-
Nyíregyháza, Венгрия, 4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Szolnok, Венгрия, 5004
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Германия, 69120
- Universitaetsklinikum Heidelberg
-
-
Bavaria
-
Munich, Bavaria, Германия, 81377
- Klinikum der Universitaet Muenchen - Campus Grosshardern
-
-
-
-
-
Athens, Греция, 15125
- Athens Medical Center
-
Athens, Греция, 11528
- General Hospital of Athens "Alexandra"
-
Athens, Греция, 14564
- General Oncology Hospital of Kifissia " Agioi Anargyroi"
-
Heraklion, Греция, 71110
- University General Hospital of Heraklion
-
Larissa, Греция, 41110
- University General Hospital of Larissa
-
Thessaloniki, Греция, 54622
- Bioclinic Thessaloniki
-
Thessaloniki, Греция, 54645
- Euromedica General Clinic Thessaloniki
-
Thessaloniki, Греция, 56429
- General Hospital Papageorgiou
-
Thessaloniki, Греция, 57001
- Interbalkan Hospital of Thessaloniki
-
-
-
-
-
Haifa, Израиль, 3109601
- Rambam Health Care Center
-
Jerusalem, Израиль, 9103102
- Shaare Zedek Medical Center
-
Jerusalem, Израиль, 9112001
- Hadassah University Hospital - Ein Kerem
-
Petah Tikva, Израиль, 49100
- Rabin Medical Center-Beilinson Campus
-
Ramat Gan, Израиль, 52363
- Chaim Sheba Medical Center
-
Rehovot, Израиль, 7610001
- Kaplan Medical Center
-
Safed, Израиль, 13100
- Ziv Medical Center
-
Tel Aviv, Израиль, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Barcelona, Испания, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Испания, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Испания, 08023
- Hospital Quironsalud Barcelona
-
Barcelona, Испания, 08003
- Hospital del Mar
-
Madrid, Испания, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Испания, 28040
- Hospital Universitario Clinico San Carlos
-
Madrid, Испания, 28034
- Hospital Ruber Internacional
-
Madrid, Испания, 28033
- MD Anderson Cancer Centre
-
Málaga, Испания, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Испания, 41009
- Hospital Universitario Virgen Macarena
-
Seville, Испания, 41013
- Hospital Universitario Virgen del Rocio
-
Valencia, Испания, 46014
- Hospital General Universitario de Valencia
-
Valencia, Испания, 46009
- Instituto Valenciano de Oncologia IVO
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08908
- ICO l'Hospitalet - Hospital Duran i Reynals
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Испания, 20014
- Hospital Universitario Donostia
-
-
La Coruña
-
A Coruña, La Coruña, Испания, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Испания, 38320
- Hospital Universitario de Canarias
-
-
Vizcaya
-
Bilbao, Vizcaya, Испания, 48013
- Hospital de Basurto
-
-
-
-
-
Bologna, Италия, 40138
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Brescia, Италия, 25100
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
-
Catania, Италия, 95125
- Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
-
Catanzaro, Италия, 88100
- Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
-
Milan, Италия, 20141
- IEO Istituto Europeo di Oncologia
-
Naples, Италия, 80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Rimini, Италия, 47923
- Ospedale degli Infermi
-
Roma, Италия, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Roma, Италия, 00133
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata
-
-
Lecce
-
Tricase, Lecce, Италия, 73039
- Azienda Ospedaliera Card. G. Panico
-
-
Milano
-
Monza, Milano, Италия, 20900
- Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
-
Rozzano, Milano, Италия, 20089
- Istituto Clinico Humanitas
-
-
Verona
-
Negrar, Verona, Италия, 37024
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T2N4N2
- Tom Baker Cancer Center
-
-
Ontario
-
Toronto, Ontario, Канада, M4N 3M5
- Toronto Sunnybrook Hospital
-
-
Quebec
-
Montreal, Quebec, Канада, H2W 1S6
- McGill University - Dept. Oncology Clinical Research Program
-
-
-
-
Anhui
-
Hefei, Anhui, Китай, 230001
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100853
- Chinese PLA General Hospital
-
Beijing, Beijing Municipality, Китай, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Fujian
-
Fuzhou, Fujian, Китай, 350025
- Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510120
- Sun Yat-sen Memorial hospital, Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Китай, 430079
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210008
- The Affiliated Drum Tower Hospital of Nanjing University
-
-
Jilin
-
Changchun, Jilin, Китай, 130000
- The First Hospital of Jilin University
-
Changchun, Jilin, Китай, 130012
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, Китай, 110042
- Liaoning Cancer Hospital & Institute
-
-
Ningxia Hui
-
Yinchuan, Ningxia Hui, Китай, 750004
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Linyi, Shandong, Китай, 276001
- Linyi Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200080
- Shanghai General Hospital
-
Shanghai, Shanghai Municipality, Китай, 20032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610041
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, Китай, 310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
-
-
-
Braga, Португалия, 4710-243
- Hospital de Braga
-
Guimarães, Португалия, 4835-044
- Centro Hospitalar do Alto do Ave, EPE
-
Lisbon, Португалия, 1649-035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Lisbon, Португалия, 1400-038
- Fundação Champalimaud
-
Matosinhos Municipality, Португалия, 4464-509
- Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
-
Porto, Португалия, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
Porto, Португалия, 4099-001
- Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
-
Santa Maria da Feira, Португалия, 4520-211
- Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
-
Vila Nova de Gaia, Португалия, 4434-502
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
-
Vila Real, Португалия, 5000-508
- Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
-
-
-
-
-
Moscow, Россия, 115478
- FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
-
Moscow, Россия, 143423
- SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
-
Yaroslavl, Россия, 150054
- SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
-
-
-
-
Cornwall
-
Truro, Cornwall, Соединенное Королевство, TR1 3LJ
- Royal Cornwall Hospital
-
-
Greater London
-
London, Greater London, Соединенное Королевство, NW3 2QG
- Royal Free Hospital
-
London, Greater London, Соединенное Королевство, EC1M 6BQ
- Queen Mary University of London
-
London, Greater London, Соединенное Королевство, NW1 2PG
- University College London Hospitals
-
-
Lothian Region
-
Edinburgh, Lothian Region, Соединенное Королевство, EH4 2XU
- Western General Hospital
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Соединенное Королевство, NG5 1PB
- Nottingham University Hospitals City Campus
-
-
Surrey
-
Guildford, Surrey, Соединенное Королевство, GU2 7XX
- Royal Surrey County Hospital
-
-
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85224
- Ironwood Cancer & Research Centers - Chandler II
-
Gilbert, Arizona, Соединенные Штаты, 85234
- Banner MD Anderson Cancer Center
-
Goodyear, Arizona, Соединенные Штаты, 85338
- Cancer Treatment Centers of America at Western Regional Medical Center
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095
- UCLA School of Medicine
-
Palo Alto, California, Соединенные Штаты, 94305
- Stanford Cancer Institute
-
Redondo Beach, California, Соединенные Штаты, 90277
- Cancer Care Associates Medical Group, Inc. TORI
-
San Francisco, California, Соединенные Штаты, 94158
- University of California at San Francisco (PARENT)
-
-
Connecticut
-
Norwich, Connecticut, Соединенные Штаты, 06360
- Eastern Connecticut Hematology/Oncology Assoc.
-
-
Delaware
-
Newark, Delaware, Соединенные Штаты, 19713
- Christiana Care Health Services, Inc.
-
-
Florida
-
Boca Raton, Florida, Соединенные Штаты, 33426
- Sylvester Comprehensive Cancer Center - Deerfield Beach
-
Fort Myers, Florida, Соединенные Штаты, 33916
- Florida Cancer Specialists (South Region)
-
Hollywood, Florida, Соединенные Штаты, 33021
- Memorial Healthcare System MRH Cancer Center
-
Orlando, Florida, Соединенные Штаты, 32806
- Orlando Health, Inc.
-
Tampa, Florida, Соединенные Штаты, 33139
- Moffitt Cancer Center -Tampa
-
-
Georgia
-
Newnan, Georgia, Соединенные Штаты, 30263
- Cancer Treatment Centers of America-Georgia
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago Medical Center
-
Zion, Illinois, Соединенные Штаты, 60099
- Cancer Treatment Centers of America
-
-
Kansas
-
Wichita, Kansas, Соединенные Штаты, 67214
- Cancer Center of Kansas
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70115
- Touro Infirmary
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Соединенные Штаты, 48202
- Henry Ford Hospital
-
-
Missouri
-
Kansas City, Missouri, Соединенные Штаты, 64111
- Saint Luke's Hospital of Kansas City
-
-
New Jersey
-
Livingston, New Jersey, Соединенные Штаты, 07039
- Saint Barnabas Medical Center
-
-
New York
-
New York, New York, Соединенные Штаты, 10016
- New York University Medical Center
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Hospital
-
New York, New York, Соединенные Штаты, 10065
- Weill Cornell Medicine Breast Center
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15219
- University of Pittsburgh Medical Center Health System
-
-
South Carolina
-
Greenville, South Carolina, Соединенные Штаты, 29601
- St Francis Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Соединенные Штаты, 37909
- Brig Center for Cancer Care and Survivorship
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Baptist Cancer Center
-
Nashville, Tennessee, Соединенные Штаты, 37201
- Tennessee Oncology - Skyline Satellite
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75234
- BloomTrials Clinical Research, LLC
-
Houston, Texas, Соединенные Штаты, 77030
- The Methodist Hospital Research Institute
-
Houston, Texas, Соединенные Штаты, 77030
- University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Virginia Cancer Specialists
-
-
-
-
-
Kaohsiung City, Тайвань, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Tainan, Тайвань, 704
- National Cheng Kung University Hospital
-
Taipei, Тайвань, 100
- National Taiwan University Hospital
-
-
-
-
-
Paris, Франция, 75020
- Hopital Tenon
-
Paris, Франция, 75005
- Institut Curie - site de Paris
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Франция, 13009
- Institut Paoli Calmettes
-
-
Calvados
-
Caen, Calvados, Франция, 14076
- Centre François Baclesse
-
-
Cotes d'Armor
-
Plérin, Cotes d'Armor, Франция, 22190
- CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
-
-
Finistere
-
Brest, Finistere, Франция, 29609
- CHU Brest - Hôpital Morvan
-
-
Gironde
-
Bordeaux, Gironde, Франция, 33076
- Institut Bergonié
-
-
Herault
-
Montpellier, Herault, Франция, 34070
- Clinique Clementville
-
Montpellier, Herault, Франция, 34298
- Institut Régional du Cancer de Montpellier
-
-
Ille Et Vilaine
-
Rennes, Ille Et Vilaine, Франция, 35042
- CRLCC Eugene Marquis
-
-
Loire Atlantique
-
Saint-Herblain, Loire Atlantique, Франция, 44805
- ICO - Site René Gauducheau
-
-
Loiret
-
Le Puy-en-Velay, Loiret, Франция, 43012
- Centre Hospitalier Emile Roux
-
-
Maine Et Loire
-
Angers, Maine Et Loire, Франция, 49055
- ICO - Site Paul Papin
-
-
Nord
-
Valenciennes, Nord, Франция, 59322
- Centre Hospitalier Valenciennes
-
-
Paris
-
Paris, Paris, Франция, 75475
- Hôpital Saint-Louis - Paris
-
-
Sarthe
-
Le Mans, Sarthe, Франция, 72015
- Clinique Victor Hugo - Centre Jean Bernard
-
-
Vaculuse
-
Avignon, Vaculuse, Франция, 84918
- Institut Sainte Catherine
-
-
Val De Marne
-
Saint-Mandé, Val De Marne, Франция, 94160
- Hôpital d'Instruction des Armees Begin*
-
Villejuif, Val De Marne, Франция, 94805
- Institut Gustave Roussy
-
-
-
-
-
Aarau, Швейцария, 5000
- Hirslanden Medical Center
-
Basel, Швейцария, 4031
- Universitaetsspital Basel
-
Chur, Швейцария, 7000
- Kantonsspital Graubuenden
-
Lausanne, Швейцария, 1011
- Centre Hospitalier Universitaire Vaudois
-
Sankt Gallen, Швейцария, 9007
- Kantonsspital St. Gallen
-
Winterthur, Швейцария, 8401
- Kantonsspital Winterthur
-
Zurich, Швейцария, 8091
- Universitaetsspital Zuerich
-
-
-
-
-
Solna, Швеция, 17176
- Karolinska universitetssjukhuset - Solna
-
Sundsvall, Швеция, 85186
- Länssjukhuset Sundsvall-Härnösand
-
Uppsala, Швеция, 75185
- Akademiska Sjukhuset
-
-
-
-
-
Daegu, Южная Корея, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Южная Корея, 03080
- Seoul National University Hospital
-
Seoul, Южная Корея, 05505
- Asan Medical Center
-
Seoul, Южная Корея, 06351
- Samsung Medical Center
-
Seoul, Южная Корея, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Южная Корея, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Южная Корея, 10408
- National Cancer Center
-
Incheon, Gyeonggi-do, Южная Корея, 22332
- Inha University Hospital
-
Seongnam-si, Gyeonggi-do, Южная Корея, 13620
- Seoul National University Bundang Hospital
-
Suwon, Gyeonggi-do, Южная Корея, 16499
- Ajou University Hospital
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, Южная Корея, 361-711
- Chungbuk National University Hospital
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 464-8681
- Aichi Cancer Center Hospital
-
-
Chiba
-
Kashiwa-shi, Chiba, Япония, 277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama, Ehime, Япония, 791-0280
- NHO Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka, Fukuoka, Япония, 811-1395
- NHO Kyushu Cancer Center
-
-
Fukushima
-
Fukushima, Fukushima, Япония, 960-1295
- Fukushima Medical University Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, Япония, 730-8518
- Hiroshima City Hiroshima Citizens Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 003-0804
- NHO Hokkaido Cancer Center
-
-
Hyōgo
-
Nishinomiya-shi, Hyōgo, Япония, 663-8501
- Hyogo College of Medicine Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Япония, 892-0833
- Hakuaikai Sagara Hospital
-
-
Kanagawa
-
Isehara, Kanagawa, Япония, 259-1193
- Tokai University Hospital
-
Yokohama, Kanagawa, Япония, 241-8515
- Kanagawa Cancer Center
-
-
Osaka
-
Osaka, Osaka, Япония, 540-0006
- NHO Osaka National Hospital
-
-
Osakasayama-shi
-
Onohigashi, Osakasayama-shi, Япония, 589-8511
- Kindai University Hospital
-
-
Saitama
-
Kitaadachi-gun, Saitama, Япония, 362-0806
- Saitama Cancer Center
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Япония, 411-8777
- Shizuoka Cancer Center
-
-
Tokyo-To
-
Kōtoku, Tokyo-To, Япония, 135-8550
- Cancer Institute Hospital of JFCR
-
Minatoku, Tokyo-To, Япония, 105-8470
- Toranomon Hospital
-
Shinagawa-Ku, Tokyo-To, Япония, 142-8666
- Showa University Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Is the age of majority in their country
-
Has pathologically documented breast cancer that:
- Is unresectable or metastatic
- Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- Is HR-positive or HR-negative
- Has progressed on, and would no longer benefit from, endocrine therapy
- Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
- Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
-
Has documented radiologic progression (during or after most recent treatment)
-
Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:
- assessment of HER2 status
- assessment of post-treatment status
-
Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1
-
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
-
Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)
Exclusion Criteria:
- Is ineligible for all options in the physician's choice arm
- Has breast cancer ever assessed with high-HER2 expression
- Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
- Has uncontrolled or significant cardiovascular disease
- Has spinal cord compression or clinically active central nervous system metastases
- Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Trastuzumab deruxtecan
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a |
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Другие имена:
|
|
Активный компаратор: Physician's Choice
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
|
Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Временное ограничение: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Общее количество случаев выживания (смертей)
Временное ограничение: С даты рандомизации до даты смерти по любой причине, примерно до 3 лет
|
С даты рандомизации до даты смерти по любой причине, примерно до 3 лет
|
|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Временное ограничение: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Временное ограничение: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Временное ограничение: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Временное ограничение: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in All Patients
Временное ограничение: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Временное ограничение: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Временное ограничение: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Временное ограничение: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
|
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Временное ограничение: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
All-Cause Mortality
Временное ограничение: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Global Clinical Leader, Daiichi Sankyo
Публикации и полезные ссылки
Общие публикации
- Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
- Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18.
- Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
- Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
- Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3.
- Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
- Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13.
- Iyengar AR, Downs EP, Mehta S, Rangarajan N, Woo MS, Sredni ST, Donato RD, Simsek S, Wilson DM, Krieser K, Patzke EB, Kyek N, Anderson C, Wagner T, Hipp J, Nassar A, Barman H. HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0. Breast J. 2026;2026(1):e7212120. doi: 10.1155/tbj/7212120.
- Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4. Epub 2025 Oct 8.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования по локализации
- Новообразования
- Неопластические процессы
- Кожные заболевания
- Заболевания груди
- Патологические состояния, признаки и симптомы
- Заболевания кожи и соединительной ткани
- Новообразования молочной железы
- Метастаз новообразования
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Нуклеиновые кислоты, нуклеотиды и нуклеозиды
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Таксииды
- Циклодеканы
- Diterpenes
- Дезоксицитидин
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Нуклеозиды
- Урацил
- Пиримидиноны
- Дезоксирибонуклеозиды
- Флуорурацил
- Капецитабин
- Гемцитабин
- Паклитаксел
- 130-нм-паклитаксел
- Trastuzumab Deruxtecan
- Эрибулин
Другие идентификационные номера исследования
- DS8201-A-U303
- 2018 (Грант/контракт NIH США)
- 2018-003069-33 (Номер EudraCT)
- 184223 (Идентификатор реестра: JAPIC CTI)
- DESTINY-B04 (Другой идентификатор: Daiichi Sankyo and AstraZeneca)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Сроки обмена IPD
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Критерии совместного доступа к IPD
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .